CD31 peptides

US10815272B2 · kind B2 · utility

Assignees

• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• UNIVERSITÉ PARIS DIDEROT—PARIS 7 · FR
• UNIVERSITE PARIS 13 - PARIS NORD · FR
• ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR

Inventors

• Giuseppina Caligiuri · Paris, FR
• Antonino Nicoletti · Paris, FR

Key dates

• Filing date: Jun 19, 2013
• Grant date: Oct 27, 2020
• Expiry date: Jun 19, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides peptides corresponding to fragments of CD31 that inhibit platelet and leukocyte activation, and to their use in the treatment of thrombotic disease. These peptides find use as therapeutic agents in the treatment of inflammatory diseases and thrombotic diseases such as atherothrombosis, in particular when immobilised onto solid supports.